The ARHGDIA Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARHGDIA gene has been disrupted in the HAP1 cell line. This product provides a heterogeneous pool of edited cells, enabling functional studies of ARHGDIA loss-of-function while preserving the genetic diversity of a polyclonal population. As a polyclonal knockout, it avoids clonal artifacts and is well-suited for applications requiring bulk cellular responses.
HAP1 is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia cell line. It grows as an adherent monolayer and contains a single copy of most chromosomes, which simplifies genetic manipulation and phenotypic interpretation. The near-haploid karyotype reduces the likelihood of heterozygous confounding effects, making HAP1 an ideal platform for targeted gene knockout studies. Its leukemic origin also offers context for investigating signaling pathways relevant to hematopoietic malignancies and cancer cell biology.
ARHGDIA (Rho GDP dissociation inhibitor alpha) functions as a key regulator of Rho GTPase signaling by inhibiting GDP dissociation from Rho family proteins, thereby maintaining them in an inactive state. It interacts directly with RhoA, Rac1, and Cdc42, and its activity is modulated by upstream kinases including Src, PAK, and PKC. ARHGDIA??s regulatory role extends to actin cytoskeleton dynamics, focal adhesion turnover, and cell migration. Downstream effectors such as ROCK, PAK, LIMK, and cofilin mediate cytoskeletal reorganization. Disruption of ARHGDIA leads to unregulated Rho GTPase activation, enhanced actin polymerization, and increased cell motility, with potential effects on proliferation and apoptosis.
In the HAP1 cellular context, ARHGDIA knockout generates a model in which the balance of Rho GTPase activity is perturbed against a near-haploid genetic background. This system allows researchers to probe the consequences of abrogated ARHGDIA function on migration and adhesion in a cancer cell line of myeloid origin. The polyclonal nature of the knockout population preserves the stochastic integration of gene disruption events, which can partially mimic heterogeneous tumor cell populations. Consequently, this model is particularly relevant for studying mechanisms of cancer metastasis, where diverse cell migration phenotypes contribute to disease progression.
The ARHGDIA Knockout HAP1 Polyclonal Cells are designed for a range of experimental approaches, including western blotting for Rho GTPase expression, immunofluorescence analysis of actin structures, and migration or invasion assays. Activation states of Rho family proteins can be assessed using Rho activation pull-down assays, and proliferation can be monitored to evaluate the impact of ARHGDIA loss on cell growth. These applications support investigations into cancer biology, Rho GTPase signaling, and drug target validation. For further details or to acquire this product for your research, please contact Ascent Research.
